<DOC>
	<DOCNO>NCT00524667</DOCNO>
	<brief_summary>OBJECTIVES To investigate : - mechanism Valproic Acid ( VPA ) -induced apoptosis B-CLL - ability VPA combination standard chemotherapy new antitumor agent induce synergistic antitumor effect chronic lymphocytic leukemia ( CLL ) cell - clinical efficacy VPA previously treat CLL patient . This example translational research study result laboratory study apply clinical trial CLL clinic CancerCare Manitoba .</brief_summary>
	<brief_title>HDAC Inhibitor Valproic Acid Effective Therapy Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>All participant treat valproic acid ( VPA ) start dose 15 mg/kg/day orally divide dos . This dose produce VPA plasma level 346-693 μM recommend start dose patient seizure disorder . Each week pre-dose serum VPA level determine immunoassay daily dose increase 5 mg/kg/d ensure predose level &gt; 1mM . Once target dose achieve serum VPA level determine monthly basis ensure pre dose level &gt; 1mM . After complete 28 day therapy participant examine lab work drawn ( CBC differential , electrolytes , BUN , creatinine , total protein , albumin , calcium , LDH , total direct bilirubin , ALT/AST , β2-microglobulin . Females child bear age undergo pregnancy test prior 28 day cycle ) . For participant identify stable progressive disease ( National Cancer Institute Criteria ) , Fludarabine ( Flu ) therapy add VPA 28 day cycle . Oral Flu administer dose 40 mg/m2/day day 1-3 28 day cycle addition VPA describe . Dose adjustment Flu base creatinine clearance . All participant receive fludarabine receive irradiate blood product pneumocystis carnii prophylaxis . Treatment continue VPA ± Flu maximum six 28 day cycle . Therapy discontinue prior six 28 day cycle : ) participant request discontinuation , b ) participant unable comply protocol , c ) medical care team think change therapy would best interest participant , ) evidence progressive disease two cycle VPA + Flu , e ) participant experience unacceptable toxicity attributable study drug ≥3 non-hematological toxicity prolong grade 4 hematological toxicity ( NCI common toxicity criterion , Table 5 protocol ) , f ) AST/ALT increase &gt; 6x upper limit normal g ) participant become pregnant .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Active CLL ( define National Cancer Institute Working Group ) Patients must receive least one prior therapy CLL treat nucleoside analogue . Recruitment limit ECOG performance status 2 less . Patients pregnant breastfeeding Patients history autoimmune cytopenia Patients platelets &lt; 50 x 109/L absolute neutrophil count &lt; 1.5X109/L Patients hepatic disease AST/ALT 6x upper limit normal Patients calculate creatinine clearance &lt; 30 ml/min use Cockroft Gault formula Patients history pancreatitis Patients receive drug affect VPA protein bind metabolism Patients active infection , HIV active viral hepatitis Patients active secondary malignancy central nervous system involvement CLL Patients diagnose aggressive lymphoproliferative disorder Richter 's transformation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Active CLL</keyword>
</DOC>